Personal tools

Lungenkarzinom

NSCLC: ICT01-101

A first-in-human, two-part, open-label, clinical study to assess the saftey, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/ refractory cancer (EVICTION ...Read More

NSCLC: Boehringer-Ingelheim 1336-0011

An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in check point inhibitor naive patient with locally advanced or metastatic nonsquamous Non-Small Cell Lung ...Read More

NSCLC: Find

A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harboring FGFR genetic alterations after relapse of standard therapy.Read More